STOCK TITAN

Precision Biosciences legal chief sells 2,821 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Precision Biosciences Inc. Chief Legal Officer Dario Scimeca sold 2,821 shares of common stock directly on November 10, 2026, at the reported price of $9.75 per share. The sale was made under a Rule 10b5-1 trading plan adopted September 29, 2025; reported sale prices ranged from $9.60 to $9.845. After the sale, Scimeca held 56,782 shares, including 3,146 shares acquired under the issuer’s 2019 Employee Stock Purchase Plan at a weighted average price of $3.61.

Insider Scimeca Dario
Role Chief Legal Officer
Sold 2,821 shs ($28K)
Share of Position Sold 4.7%
Type Security Shares Price Value
Sale Common Stock F1, F2, F3 2,821 $9.75 $28K
Holdings After Transaction: Common Stock — 56,782 shares (Direct)
Holdings Before and After: Common Stock, 59,603 to 56,782 shares (Direct)
Footnotes (3)
  1. F1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.
  2. F2. Sale prices for the transactions reported range from $9.60 to $9.845. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
  3. F3. Includes 3,146 shares acquired under the Issuer's 2019 Employee Stock Purchase Plan at a weighted average price of $3.61.
Shares sold 2,821 shares Common stock sold by Dario Scimeca on November 10, 2026
Reported price per share $9.75 per share Sale on November 10, 2026
Reported sale-price range $9.60 to $9.845 per share Prices for the reported sale transactions
Shares held after sale 56,782 shares Dario Scimeca’s direct holdings following the transaction
Employee Stock Purchase Plan shares 3,146 shares Included in the reported post-sale holdings
Employee Stock Purchase Plan weighted average price $3.61 per share Price for the 3,146 shares acquired under the issuer’s 2019 Employee Stock Purchase Plan
Rule 10b5-1 plan adoption date September 29, 2025 Adoption date of the plan governing the sale
Rule 10b5-1 trading plan regulatory
"made pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Employee Stock Purchase Plan financial
"acquired under the Issuer's 2019 Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
weighted average price financial
"at a weighted average price of $3.61"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many DTIL shares did Dario Scimeca sell, and at what price?

Dario Scimeca sold 2,821 shares on November 10, 2026, at the reported price of $9.75 per share. Reported sale prices ranged from $9.60 to $9.845. The sale was made under a Rule 10b5-1 trading plan adopted September 29, 2025.

How many DTIL shares did Dario Scimeca hold after the sale?

He held 56,782 shares after the sale. That position includes 3,146 shares acquired under Precision Biosciences Inc.’s 2019 Employee Stock Purchase Plan at a weighted average price of $3.61.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Scimeca Dario

(Last)(First)(Middle)
C/O PRECISION BIOSCIENCES, INC.
302 E PETTIGREW STREET, SUITE A-100

(Street)
DURHAM NORTH CAROLINA 27701

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
PRECISION BIOSCIENCES INC [ DTIL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Legal Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/10/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/10/2026S(1)2,821D$9.75(2)56,782(3)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.
2. Sale prices for the transactions reported range from $9.60 to $9.845. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
3. Includes 3,146 shares acquired under the Issuer's 2019 Employee Stock Purchase Plan at a weighted average price of $3.61.
Remarks:
/s/ Dario Scimeca11/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading